| 基本资料 | 总例数 | MACE组 | 非MACE组 | Statistic | P |
| 性别 |
|
|
| 3.431 | 0.082 |
| 女性，n (%) | 102 (25.6) | 32 (32.7) | 70 (23.3) |
|
|
| 男性，n (%) | 297 (74.4) | 66 (67.3) | 231 (76.7) |
|
|
| 年龄(岁) | 61.89 ± 11.83 | 67.88 ± 11.42 | 59.94 ± 11.32 | −5.730 | <0.001 |
| BMI (kg/m2) | 25.18 ± 3.35 | 25.38 ± 3.64 | 25.12 ± 3.26 | −0.663 | 0.508 |
| 危险因素，n (%) |
|
|
|
|
|
| 吸烟 | 150 (37.6) | 44 (44.9) | 106 (35.2) | 2.954 | 0.086 |
| 高血压 | 232 (58.1) | 68 (69.4) | 164 (54.5) | 6.747 | 0.009 |
| 糖尿病 | 94 (23.6) | 35 (35.7) | 59 (19.6) | 10.658 | 0.001 |
| 高脂血症 | 129 (32.3) | 28 (28.6) | 101 (33.6) | 0.839 | 0.360 |
| 冠心病家族史 | 125 (31.3) | 44 (44.9) | 81 (26.9) | 11.12 | 0.001 |
| 既往病史，n (%) |
|
|
|
|
|
| 既往PCI或CABG手术史 | 44 (11.0) | 15 (15.3) | 29 (9.6) | 2.424 | 0.120 |
| 既往心梗病史 | 68 (17.0) | 21 (21.4) | 47 (15.6) | 1.768 | 0.784 |
| LVEF (%) | 54 .68 ± 7.71 | 49.81 ± 10.13 | 56.27 ± 5.96 | −6.078 | <0.001 |
| Killip class, n (%) |
|
|
| 71.080 | <0.001 |
| Class I | 310 (77.7) | 46 (46.9) | 264 (87.7) |
|
|
| Class II | 66 (16.5) | 39 (39.8) | 27 (9.0) |
|
|
| Class III | 13 (3.3) | 7 (7.1) | 6 (2.0) |
|
|
| Class IV | 10 (2.5) | 6 (6.1) | 4 (1.3) |
|
|
| 病变血管数，n (%) |
|
|
| 5.806 | 0.055 |
| 1 | 63 (15.8) | 12 (12.2) | 51 (16.9) |
|
|
| 2 | 150 (37.6) | 30 (30.6) | 120 (39.9) |
|
|
| 3 | 186 (46.6) | 56 (57.1) | 130 (43.2) |
|
|
| 用药情况，n (%) |
|
|
|
|
|
| 双抗治疗 | 384 (96.2) | 93 (94.9) | 291 (96.7) | 0.647 | 0.540 |
| 他汀治疗 | 381 (95.5) | 93 (94.9) | 288 (95.7) | 0.105 | 0.780 |
| 临床诊断，n (%) |
|
|
| 3.114 | 0.078 |
| STEMI | 126 (31.6) | 38 (38.8) | 88 (29.2) |
|
|
| NSTEMI | 273 (68.4) | 60 (61.2) | 213 (70.8) |
|
|
| 生化指标 |
|
|
|
|
|
| TC (mmol/L) | 4.68 ± 1.20 | 4.70 ± 1.22 | 4.61 ± 1.12 | 1.074 | 0.283 |
| TG (mmol/L) | 1.74 ± 1.78 | 1.41 ± 1.02 | 1.85 ± 1.95 | −2.638 | 0.008 |
| LDL-C (mmol/L) | 2.82 ± 0.99 | 2.85 ± 0.99 | 2.71 ± 0.98 | 1.821 | 0.069 |
| HDL-C (mmol/L) | 1.18 ± 0.35 | 1.21 ± 0.35 | 1.17 ± 0.35 | −0.611 | 0.541 |
| UA (mmol/L) | 337.02 ± 97.44 | 357.53 ± 114.81 | 330.23 ± 90.20 | −2.433 | 0.015 |
| NT-proBNP (pg/mL) | 1451.49 ± 3137.78 | 3537.76 ± 5617.22 | 777.24 ± 987.42 | −8.099 | <0.001 |
| Ln (NT-proBNP) (pg/ml) | 6.24 ± 1.54 | 7.37 ± 1.32 | 5.87 ± 1.42 | −8.099 | <0.001 |
| 高敏肌钙蛋白T (ug/L) | 2.40 ± 2.94 | 3.00 ± 3.50 | 2.21 ± 2.73 | −0.622 | 0.534 |
| hs-CRP (mg/L) | 1.83 ± 0.60 | 1.86 ± 0.64 | 1.82 ± 0.59 | −1.771 | 0.077 |
| D二聚体(ng/mL) | 301.36 ± 290.06 | 438.98 ± 464.65 | 256.11 ± 181.89 | −5.744 | <0.001 |
| 糖化血红蛋白 | 12.63 ± 4.03 | 13.24 ± 4.47 | 12.43 ± 3.87 | −1.970 | 0.056 |
| 风险评分 |
|
|
|
|
|
| GRACE评分 | 127.49 ± 32.45 | 153.54 ± 32.42 | 119.00 ± 27.63 | −8.953 | <0.001 |
| TIMI评分 | 3.39 ± 1.58 | 4.60 ± 1.73 | 3.00 ± 1.31 | −7.242 | <0.001 |